Company Profile

IPCA LABORATORIES LTD.

NSE : IPCALABBSE : 524494ISIN CODE : INE571A01020Industry : Pharmaceuticals & DrugsHouse : Ipca Laboratories
BSE1849.30-16.2 (-0.87 % )
PREV CLOSE (Rs.) 1865.50
OPEN PRICE (Rs.) 1874.95
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 13332
TODAY'S LOW / HIGH (Rs.)1820.05 1874.95
52 WK LOW / HIGH (Rs.)1162 2455.55
NSE1849.55 -17.25 (-0.92 % )
PREV CLOSE(Rs.) 1866.80
OPEN PRICE (Rs.) 1851.20
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 1849.55 (741 )
VOLUME 371920
TODAY'S LOW / HIGH(Rs.) 1820.05 1863.75
52 WK LOW / HIGH (Rs.)1200 2460

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.27
TTM EPS (Rs.) 88.06
P/E Ratio 21.00
Book Value (Rs.) 350.12
Face Value (Rs.) 2
MCap (Rs. in Mn) 234587.61
Price/Earning (TTM) 18.02
Price/Sales (TTM) 4.60
Price/Book (MRQ) 5.28
PAT Margin (%) 14.94
ROCE (%) 20.84
Incorporation Year : 1949

Management Info :

Premchand Godha - Chairman Premchand Godha - Managing Director

Registered Office :

Address : 48 , Kandivli Industrial Estate,Kandivli (West), ,
Mumbai,
Maharashtra-400067

Phone : 022- 66474444

Website : www.ipcalabs.com

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX
NEWS More
19Jan01-19-2021$ Board Meeting Intimation for Unaudited Financial Results For The 3Rd Quarter And Nine Months Ended 31St December, 2020 Of The Financial Year 2020-21 Board Meeting Intimation fo
IPCA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2021 ,inter alia, to consider and approve Unaudited Financial Results for the 3rd quarter and nine months ended 31st December, 2020 of the financial year 2020-21
IPCA LABORATORIES LTD.has informed BSE that the meeting of the..
30Nov11-30-2020$Ipca Laboratories informs about disclosure Ipca Laboratories informs ab
Ipca Laboratories has informed that it has enclosed disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above information is a part of company’s filings submitted to BSE.

Ipca Laboratories has informed that it has enclosed disclosure..
27Oct10-27-2020$Ipca Laboratories to hold board meeting Ipca Laboratories to hold bo

Ipca Laboratories has informed that the meeting of the Board of Directors of the Company is scheduled on 07/11/2020, to consider and take on record the Unaudited Financial Results for the 2nd quarter and half year ended 30th September, 2020 of the financial year 2020-21; and to consider declaration of Interim Dividend for the financial year 2020-21.

The above information is a part of company’s filings submitted to BSE.

Ipca Laboratories has informed that the meeting of the Board of..
18Sep09-18-2020$Ipca Laboratories informs about proceedings of 70th AGM Ipca Laboratories informs ab

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Ipca Laboratories has informed that it has enclosed the proceedings at the 70th Annual General Meeting (AGM) of the Company held on 17th September, 2020.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 of the Securities and Exchange Board..
18Sep09-18-2020$Ipca Laboratories informs about voting results of 70th AGM Ipca Laboratories informs ab

Pursuant to Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Ipca Laboratories has informed that it has enclosed the results of the voting on the proposed resolutions along with the Consolidated Report on the voting issued by Jigyasa N. Ved of Parikh & Associates, Practising company Secretaries, Scrutinizer appointed for the 70th Annual General Meeting (AGM) of the Company held on 17th September, 2020. In this regard, note that all the five (5) resolutions placed before the shareholders as per the notice of the Annual General Meeting have been passed by requisite majority.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 44 of the Securities and Exchange Board..
Financials More
Rs. in Millions
QTR Dec 20 ANNUAL 20
Net Profit2599.76524.6
Gross Profit 3152.6 7849.7
Operating Profit 3644.89794.5
Net Sales 13152.243674.3
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Sanofi India (BSE)
 8268.85 (1.40%)
M.Cap ( in Cr)
19043.68
Abbott India (BSE)
 14396.65 (0.34%)
M.Cap ( in Cr)
30591.88
Orchid Pharma (BSE)
 885.15 (5.00%)
M.Cap ( in Cr)
3612.86
Alembic Pharma (BSE)
 919.15 (2.38%)
M.Cap ( in Cr)
18067.10
Natural Capsules (BSE)
 117.40 (19.98%)
M.Cap ( in Cr)
73.17
Shareholding Pattern More
PROMOTERS 46.29 %
FI/BANKS/INSURANCE 3.23 %
MUTUAL FUNDS/UTI 20.58 %
NON-INSTITUTION 10.99 %
GOVERNMENT 0.28 %
FII 0 %
F & O Quotes